Trial Profile
An Observational Study of GIOTRIF (Afatinib) for First Line Therapy in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR)-Mutations
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Osimertinib
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms GIDEON
- Sponsors Boehringer Ingelheim
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 10 Sep 2019 Results of a pooled analysis of Asian phase IIIB trial and a German non-interventional study assessing the sensitivity of uncommon EGFR mutations to afatinib, presented at the 20th World Conference on Lung Cancer
- 09 Jan 2019 Status changed from active, no longer recruiting to completed.